SARS-CoV-2 spike protein promotes inflammatory cytokine activation and aggravates rheumatoid arthritis, Cell Communication and Signaling

$ 13.50

4.8 (758) In stock

Background Coronavirus disease 2019 (COVID-19) induces inflammation, autoantibody production, and thrombosis, which are common symptoms of autoimmune diseases, including rheumatoid arthritis (RA). However, the effect of COVID-19 on autoimmune disease is not yet fully understood. Methods This study was performed to investigate the effects of COVID-19 on the development and progression of RA using a collagen-induced arthritis (CIA) animal model. Human fibroblast-like synoviocytes (FLS) were transduced with lentivirus carrying the SARS-CoV-2 spike protein gene in vitro, and the levels of inflammatory cytokine and chemokine expression were measured. For in vivo experiments, CIA mice were injected with the gene encoding SARS-CoV-2 spike protein, and disease severity, levels of autoantibodies, thrombotic factors, and inflammatory cytokine and chemokine expression were assessed. In the in vitro experiments, the levels of inflammatory cytokine and chemokine expression were significantly increased by overexpression of SARS-CoV-2 spike protein in human FLS. Results The incidence and severity of RA in CIA mice were slightly increased by SARS-CoV-2 spike protein in vivo. In addition, the levels of autoantibodies and thrombotic factors, such as anti-CXC chemokine ligand 4 (CXCL4, also called PF4) antibodies and anti-phospholipid antibodies were significantly increased by SARS-CoV-2 spike protein. Furthermore, tissue destruction and inflammatory cytokine level in joint tissue were markedly increased in CIA mice by SARS-CoV-2 spike protein. Conclusions The results of the present study suggested that COVID-19 accelerates the development and progression of RA by increasing inflammation, autoantibody production, and thrombosis. Video Abstract

Cells, Free Full-Text

Immuno, Free Full-Text

SARS-CoV-2 spike protein worsens rheumatoid arthritis in mice

FOXP3 Antibody PE 12-5773-82 from Thermo Fisher Scientific

Long‐lived macrophage reprogramming drives spike protein‐mediated inflammasome activation in COVID‐19

The state of complement in COVID-19

COVID-19 Infection and Circulating Microparticles—Reviewing Evidence as Microthrombogenic Risk Factor for Cerebral Small Vessel Disease

Viruses: What triggers inflammation in COVID-19?

Glycobiology of rheumatic diseases

Bioactive lipid-based therapeutic approach to COVID-19 and other similar infections

Cytokine Storm and its Implication in Coronavirus disease 2019 (COVID-19)

Current prospects of type II interferon γ signaling and autoimmunity - Journal of Biological Chemistry

SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells